Passage Bio (PASG)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	52.77 mm	52.77 mm	52.77 mm	52.77 mm	52.77 mm	52.77 mm
Cash burn (monthly)	1.62 mm	(no burn)	2.89 mm	4.14 mm	1.62 mm	2.79 mm
Cash used (since last report)	5.79 mm	n/a	10.33 mm	14.83 mm	5.79 mm	9.99 mm
Cash remaining	46.98 mm	n/a	42.45 mm	37.94 mm	46.98 mm	42.79 mm
Runway (months of cash)	29.0	n/a	14.7	9.2	29.0	15.3

Beta Read what these cash burn values mean

Financial data from Passage Bio earnings reports.

Institutional ownership, Q4 2024

PASG institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	52	50	+4.0%
Opened positions	11	35	-68.6%
Closed positions	9	5	+80.0%
Increased positions	10	3	+233.3%
Reduced positions	10	0	NEW

13F shares	Current	Prev Q	Change
Total value	21.16 bn	26.52 bn	-20.2%
Total shares	48.98 mm	50.01 mm	-2.1%
Total puts	0.00	0.00
Total calls	15.90 k	7.70 k	+106.5%
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Lynx1 Capital Management	9.26 mm	$5.25 bn	+9.8%
Orbimed Advisors	7.40 mm	$4.20 bn	-24.6%
Vestal Point Capital	6.10 mm	$3.46 bn	0.0%
Access Industries	2.62 mm	$16.62 mm	0.0%
Frazier Life Sciences IX	2.54 mm	$2.38 mm	0.0%
New Leaf Ventures III	2.50 mm	$63.87 mm	0.0%
New Leaf Venture Partners, L.L.C.	2.50 mm	$1.42 bn	0.0%
Erste Asset Management GmbH	2.46 mm	$1.63 bn	0.0%
LAV Prescience	2.20 mm	$13.97 mm	0.0%
Vanguard	2.07 mm	$1.17 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
Orbimed Advisors	7.40 mm	-2.42 mm	-24.6%
Lynx1 Capital Management	9.26 mm	+830.00 k	+9.8%
MS Morgan Stanley	812.44 k	+799.00 k	+5944.1%
Citadel Advisors	0.00	-402.53 k	EXIT
Shay Capital	225.26 k	+133.01 k	+144.2%
Jane Street	78.19 k	+65.92 k	+537.2%
Landscape Capital Management, L.L.C.	0.00	-53.92 k	EXIT
Tower Research Capital	54.48 k	+49.45 k	+983.1%
Two Sigma Investments	49.36 k	-48.68 k	-49.6%
Squarepoint Ops	64.10 k	+36.17 k	+129.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PASG insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
8 Jan 26	Kathleen Borthwick	Common Stock	Sell	Dispose S	No	No	18.4394	2,062	38.02 k	5,402
8 Jan 26	Kathleen Borthwick	Common Stock	Option exercise	Acquire M	No	No	0	5,000	0.00	7,464
8 Jan 26	Kathleen Borthwick	RSU Common Stock	Option exercise	Dispose M	No	No	0	5,000	0.00	5,000
8 Jan 26	William Chou	Common Stock	Sell	Dispose S	No	No	18.4394	4,076	75.16 k	6,524
8 Jan 26	William Chou	Common Stock	Option exercise	Acquire M	No	No	0	10,000	0.00	10,600
8 Jan 26	William Chou	RSU Common Stock	Option exercise	Dispose M	No	No	0	10,000	0.00	10,000
15 Sep 25	Lynx1 Capital Management	Common Stock	Buy	Acquire P	Yes	No	6.9895	11,900	83.18 k	623,704
12 Sep 25	Lynx1 Capital Management	Common Stock	Buy	Acquire P	Yes	No	6.9908	19,783	138.30 k	611,804
11 Sep 25	Lynx1 Capital Management	Common stock, $0.0001 par value per share (Common Stock)	Buy	Acquire P	Yes	No	6.9558	325	2.26 k	592,021
24 Jul 25	Lynx1 Capital Management	Common Stock	Buy	Acquire P	Yes	No	5.7127	66,423	379.45 k	591,696

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Monday's Intraday Session

5 Jan 26

Chardan Capital Maintains Buy on Passage Bio, Raises Price Target to $21

12 Nov 25

Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and raises the price target from $6 to $21.